Implications of Treatment Affordability Issues

EP: 1.The Impact of Multiple Sclerosis on Quality of Life

EP: 2.Increased Prevalence of MS in Various Patient Subpopulations

EP: 3.The Importance of Early Diagnosis and Treatment in Patients with MS

EP: 4.Future Directions in Health Equity for MS Treatment

EP: 5.Challenges to Equal Access in MS Treatment

EP: 6.Impact of Limited Care for Patients with Chronic Disease

EP: 7.Population Disparities in Health Equity and Managed Care

Now Viewing

EP: 8.Implications of Treatment Affordability Issues

EP: 9.Importance of Payer/Clinician Agreement in Patient Treatment

EP: 10. Practical Steps to Mitigating Health Iniquity

In a consensus paper updated in 2019, the MS Coalition stated that giving patients access to all FDA-approved DMTs was imperative for optimal management of MS. A broad range of therapy options are important for adults with early and active disease — the latter being more likely to be experienced by Black or Hispanic patients. In addition, because Black patients may experience lower efficacy with certain DMTs, therapy options should not be restricted for this population. (14)

Conclusions